Objective:

To explore the expression, prognostic implications, and functional roles of PPFIA1 across various cancers, with a focus on pancreatic cancer.

Approach:

• Data Integration: Utilized pan-cancer datasets (TCGA, GTEx, TISCH) to assess PPFIA1 expression, genomic alterations, and pathway enrichment.
• Survival Analysis: Conducted Kaplan-Meier survival analysis and Cox regression to evaluate prognostic significance.
• External Validation: Validated findings in pancreatic cancer using external cohorts (GSE28735, GSE52452).
• Functional Analysis: Performed ShRNA-mediated knockdown in pancreatic cancer cell lines to assess proliferation, migration, and invasion.

Key Findings:

• PPFIA1 is overexpressed in pancreatic adenocarcinoma compared to non-tumor tissue.
• High PPFIA1 expression correlates with poor prognosis in pancreatic cancer.
• Genomic alterations include amplifications in head/neck cancers and mutations in endometrial carcinoma.
• GSEA analysis indicates activation of mitotic spindle assembly and EMT pathways in pancreatic cancer.
• Knockdown of PPFIA1 reduces proliferation, migration, invasion, and tumor growth in pancreatic cancer models.

Interpretation:

PPFIA1 is associated with significant prognostic value and an oncogenic role in pancreatic cancer, particularly related to EMT-related phenotypes.

Limitations:

• The study primarily relies on publicly available datasets, which may have inherent biases.
• Functional validation was limited to specific pancreatic cancer cell lines.

Conclusion:

Further investigation of PPFIA1 is warranted based on its observed roles in pancreatic cancer.